Janssen Biotech, Inc.

Janssen Pharmaceutica Nv

Hong Xie

Tongfei Wu

Kathryn Elizabeth Packman

Dirk Brehmer

Theresa Marie McDevitt

Nahor Haddish-Berhane

Edward Attiyeh

Josh Lauring

Geert S J Mannens

Shoba Shetty

Junguo Zhou

James G Greger

Yue Guo

Kyounghwa Bae

Hillary Joy Millar Quinn

Anthony T Greway

Christina Lourdes Mayer

The present invention relates to methods of treating cancers with antagonistic anti-PD-1 antibodies, formulations of the antagonistic anti-PD-1 antibodies and drug products of the anti-PD-1 antibodies.

Methods of treating cancers with antagonistic anti-PD-1 antibodies

Bispecific monoclonal antibodies and methods for treating cancer are set forth herein.

Methods of treating prostate cancer with an anti-PSMA/CD3 antibody

The present disclosure provides methods for treating a human patient diagnosed with a cancer, comprising administering a therapeutically effective amount of a PRMT5 (protein arginine methyltransferase 5) inhibitor, certain methods comprising (i) administering to the patient initial doses of at least about 0.1 mg per day of the PRMT5 inhibitor that is (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol or a pharmaceutically acceptable addition salt or solvate thereof for an initial dosing period of about 5 to about 21 days; and (ii) administering to the patient subsequent doses of at least about 0.1 mg per day of the PRMT5 inhibitor for one or more subsequent dosing periods of about 5 to about 21 days each. In these methods, a first subsequent dosing period is separated in time from the initial dosing period by at least about 5 days and the subsequent dosing periods are separated in time from each other by at least about 5 days.

Methods of treating cancer using PRMT5 inhibitors

Growing community of inventors

Dresher, PA, United States of America

Hong Xie